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ARDS = acute respiratory distress syndrome; HGMB1 = high mobility group B1; ICU = intensive care unit; IL = interleukin; MOF = multi-organ
failure; NDD = neurological determination of brain death; PaO2/FiO2 = arterial oxygen tension/inspired oxygen ratio; SARS = severe acute respira-
tory syndrome; VAP = ventilator-associated pneumonia.
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The eighth annual Toronto Critical Care Symposium was held
from 30 October to 1 November 2003, in downtown
Toronto, Ontario, Canada. This symposium is Canada’s
premier critical care conference and attracts participants
from across the country, the United States, Europe, Australia
and Asia. The attendance this year was in excess of
900 people and included the disciplines of medicine, nursing,
respiratory therapy and other allied health care professionals.
The themes of this year’s meeting included sepsis, organ
donation, blood conservation strategies, acute lung injury and
ethics. In addition, many of the plenary addresses reviewed
the recent severe acute respiratory syndrome (SARS) crisis.
The discussion surrounding SARS was particularly poignant
as Toronto was the North American city most affected by the
outbreak.
Severe acute respiratory syndrome
John Marshall (University of Toronto) kicked off the meeting
with an informative review of the epidemiology of SARS:
‘How it got from A to B’. The origin of the disease in humans
may have developed through contact with animal reservoirs
for the virus. Indeed, the first affected individuals were food
handlers who routinely came into contact with animals such
as the Civet Cat that are sold as a delicacy in Chinese
markets.
The Metropole Hotel in the Kowloon province of Hong Kong
has become perhaps one of the most infamous hotels in the
world as it is regarded as the source of the index cases for
SARS in Toronto, Hong Kong, Singapore and Hanoi. Upon
return to Toronto one of the exposed hotel guests became ill
and was taken care of by her son at home. Although she
never sought medical attention (she eventually died), her son
became ill and sought medical attention at Scarborough
Grace Hospital in Toronto. It was with this visit that the health
care system in Toronto became involved in the spread of
SARS, with devastating consequences. There were a total of
375 cases in Ontario and there are presently 43 deaths
attributed to SARS.
In Toronto the primary spread of the disease was within the
hospitals of the Greater Toronto area, essentially making
SARS a ‘nosocomial’ illness. Following the initial outbreak a
second wave of infection occurred in Toronto following
exposure of patients and hospital staff to an elderly male
patient in a convalescent home recovering from a hip
fracture. SARS II, therefore, was probably the result of
premature relaxation of infection control measures and the
late recognition of epidemiological linkages between cases.
Why Toronto? This is a question that is somewhat difficult to
answer. Marshall felt that several factors conspired to make
Toronto a probable target. Ease of travel, being a large
cosmopolitan city, inadequate facilities and lax infection
control were all cited as contributing factors. However, just
plan bad luck was probably the largest contributor to the
choice of Toronto by the SARS coronavirus
The medical system was ill prepared for SARS. Indeed, the
successful control of the infection was made through sheer
will and tireless determination of individuals. Judith Stein
(University of Toronto) focused on several of the lessons to be
learned from the way SARS was handled. Through her own
investigative efforts she drew some distressing distinctions
between the private and public sectors’ ability to deal with
crisis in any form. She paralleled the private sectors response
to the September 11th terror attacks in the United States with
the public sector’s ability to deal with the SARS crisis.
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Most of the major financial institutions in North America have
plans in place for disasters to allow them to rapidly and
effectively continue to provide service to their customers.
Planning for the unexpected is all part of a sound ‘business
continuity plan’ and not to do so would be foolish and would
probably result in loss of revenue and possibly bankruptcy
during times of crisis. These business leaders not only ensure
that systems and infrastructure have redundancy, but ensure
that the people who are integral for the basic function of the
organization are backed up. Redundancy is not a ‘bad word’
in the private sector; it is actually good business when
applied properly.
Stein has presented these thoughts to deputy ministers in the
Canadian government and has received what she interpreted
as a less than receptive response. However, Stein provided
the audience with a sound argument for the development of
an action plan and the notion that the health care sector
cannot afford to ignore the ‘back up’ of systems and human
resources — the next time we may not be so fortunate.
Continuing on the SARS theme, Donald Low (University of
Toronto) presented a further review on the outbreak in
Toronto. Low remains an integral member of the local,
provincial and international effort to control the spread of this
disease. He was truly on the ‘front lines’ during the crisis in
Toronto. Low described the two phases of the outbreak that
occurred in Toronto and relayed the absolute devastation
that was felt by the entire health care community and the
public when the second outbreak of SARS occurred in
Toronto. However, he passed on some lessons that were
learned, that may help limit spread if SARS rears its ugly
head again. The importance of infection control procedures
and lasting vigilance was emphasized.
The period of infectivity and the range of incubation periods
have been a cause for concern and debate. The disease in
general is not infectious prior to the onset of symptoms, but
the incubation period has been variably reported and in some
instances may extend beyond 10 days. At present, however,
the 10-day incubation, and hence quarantine, period remains.
The disease itself peaks in infectivity at the 7-day to 10-day
mark. In addition, there does seem to be the phenomenon of
‘super spreaders’, who may have an increased capacity to
infect those that come into contact with them. There is
generally increased risk of spread with prolonged patient
contact, in a linear fashion. At present there is no evidence of
a prolonged carrier state.
Patients can develop severe pneumonia and acute lung injury
once ill with SARS. Stephen Lapinsky (University of Toronto)
presented a review of Toronto’s intensive care unit (ICU)
experience with SARS. The mortality associated with a SARS
patient who required admission to the ICU was about
40–50%. Multiple therapies were attempted, such as
antivirals, steroids and a variety of modes of mechanical
ventilation [1,2]. Of particular interest to the audience was
the safety precautions required while caring for a SARS
patient. Certain procedures have been identified as high risk
for health care workers, not the least of which is assisting or
performing intubation. High-risk procedures combined with
the high-risk SARS patient require extraordinarily strict
precautions and the use of full protective equipment.
Transfusion medicine
The session on transfusion practices began with Dean
Fergusson’s (University of Ottawa) update on the
effectiveness of leukoreduction (the removal of white blood
cells from donated blood). Leukoreduction essentially
reduces the average white blood cell content in a unit of
packed cells from 3.0×109 to 2.5×105. The rationale for
leukoreduction is to minimize exposure to transfused
leukocytes, which can lead to adverse transfusion reactions
or alterations in immunity or inflammation. Since 1999 all
blood in Canada has been leukoreduced. A large Canadian
study recently examined the effect of this change in practice
in adult high-risk surgical patients [3]. Fergusson reviewed
the findings of their trial that showed a reduction in mortality,
fever and antibiotic use, but failed to demonstrate a change
in serious nosocomial infection. Similarly, when they
evaluated the effects in neonates (<1250g) there was
evidence of decreased morbidity and ICU stay following the
implementation of leukoreduction [4].
A reduction in transfusion rates in the ICU may help to
reduce possible harm from blood products. Between 20
and 30% of all blood transfusions occur in the ICU setting,
and 85% of patients present in an ICU for longer than
1 week receive a transfusion [5]. Higher transfusion rates
have been associated with an increased length of stay and
increased mortality versus matched controls [6]. Robert
Fowler (University of Toronto) proposed several
approaches to decrease the frequency of, and possibly the
need for, transfusion in the ICU. Perioperatively, the use of
autologous donation, the use of normovolemic
hemodilution and the use of cell recovery are possible
options. Implementation of a lower hemoglobin threshold
for transfusion, limitation in the use of ‘routine’ daily
laboratory work, the use of antifibrinolytics, the use of
erythropoietin and a reduction in the amount of phlebotomy
performed for the purposes of laboratory testing were all
suggested in the ICU. In fact, one ICU study indicated that
phlebotomy rates and volumes directly accounted for 30%
of all blood transfusions [5]. The use of pediatric
phlebotomy tubes in adults and having closed arterial line
systems to reduce wastage are viable options that have
been shown to significantly reduce blood loss from
phlebotomy [7,8].
A large multicenter trial is underway to look at the
effectiveness of some of these simple measures to reduce
transfusion. The role of blood substitutes remains futuristic.60
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David Mazar (University of Toronto) reviewed the stormy
experience to date with blood substitutes as an alternative to
blood products. Although many alternatives are on the
horizon, safety concerns and lack of proof of efficacy have
limited their clinical application.
Many of the aforementioned issues have become topical in
critical care, in no small part due to the work of Paul Hebert
(University of Ottawa). In a talk appropriately entitled, ‘Still
70?’, Hebert revisited the question of what hemoglobin value
should be the threshold for transfusion. It seems that clinical
practice remains inconsistent. Many people maintain that a
value of 70g/l remains the hemoglobin threshold for
transfusion. However, what people think and what they do in
daily practice seems to be different. This disparity was
emphasized in the anemia and blood transfusion in critically ill
patients (ABC) trial. In that study of the transfusion practice
of 146 European ICUs, the average hemoglobin at which
patients were transfused was 84±1.3g/l [6]. More
randomized controlled trials are needed to answer the
question more definitively, particularly in patients with
ischemic heart disease. Hebert hinted that a value greater
than 70g/l might be reasonable in patients with ischemic
heart disease, with 80g/l being a possible threshold.
End-of-life care
Deborah Cook (McMaster University) presented ‘Predictions
and end of life decisions in the ICU’, a topic that was sobering
to many in the audience and gave food for thought surrounding
clinicians’ end-of-life decisions in a critical care setting. Given a
standard scenario, there was a wide degree of variation in ICU
clinicians’ decisions about the appropriate levels of care for the
given patient [9]. In addition, the confidence of these
management choices was highest when the decisions were
extreme in nature (i.e. withdrawal of life support) [10]. Factors
that predict the implementation of withdrawal of life support
include the use of inotropes or vasopressors, physician
prediction of an ICU survival of less than 10%, physician
prediction of poor residual cognitive function and physician
perception of the patient’s desire to limit life support [11].
Interestingly, physician prediction of ICU mortality is the
greatest independent predictor of ICU death, even greater than
the Acute Physiology and Chronic Health Evaluation II score or
the multiple organ dysfunction score. In summation, Cook
stressed that uncertainty exists, as demonstrated in multiple
studies examining confidence, predictions, perceptions and
discomfort in end-of-life decisions.
Moving on from physicians’ perceptions in end-of-life issues,
Daren Heyland’s (Queen’s University) discussion of the
experience of dying from the perspective of the patient and of
the family brought to light some areas of patient care that
require greater attention [12]. The majority of deaths in
Canada occur in a hospital setting, from medial (noncancer)
causes; however, palliative care seems oriented to cancer
patients [13]. With regards to dying in an ICU, the majority of
family members rated their satisfaction with overall care as
excellent or very good [14]. For Canadian ICU patients and
their family members the most important aspect of achieving
quality end-of-life care was having trust in the doctors looking
after you. Problem areas that were identified included a
perceived gap between patient and family needs, and a
shortfall in services to assist with care upon discharge from
hospital. To improve patient satisfaction during end of life
these gaps need to be targeted by concentrating on
continuity of care, on patient–doctor relationships and on
relief of symptoms.
The experience in adults was contrasted to that in pediatrics.
In pediatric hospitals 80% of inhospital deaths occur in the
pediatric or neonatal ICU. Yet there is minimal evidence-
based literature about end-of-life care or palliative care in
pediatric ICUs. Jacques Lacroix (University of Montreal)
emphasized during his presentation the importance of a
multidisciplinary approach to end-of-life care in children.
Caregivers rarely decide on their own about a child’s end-of-
life wishes, as parents’ views are involved in the decisions
[15,16]. The greatest source of conflict is secondary to poor
communication, and this conflict can have serious detrimental
effects on the child’s care [17]. To prevent conflict, the
information given to parents needs to be consistent. They
should be reassured that nothing will be done to hasten the
death of the child and that drugs will be used only for comfort
and palliation [18].
The European experience surrounding issues of organ
donation was reviewed by Jean-Louis Vincent (University of
Brussels). He based his philosophical discussion on the four
main pillars of medical ethics: autonomy, beneficence,
nonmaleficence and distributive justice. During his
discussion, Vincent emphasized that any decisions about
organ donation needed to represent a balance of these four
concepts. Vincent contrasted the North American style of
obtained consent for organ donation with the approach of
presumed consent practiced in some European centers. In
the latter situation, citizens have to register their objection to
organ donation or it is presumed that they are willing donors.
It was emphasized, however, that if a family of a brain-dead
patient indicated that they felt their loved one was against
donating, then those wishes should and would be respected.
Finally, the issue of nonheart-beating donors was touched
upon, and further debate is almost certain as this is
becoming a hot topic in transplant and critical care medicine.
To bring the session on end-of-life care to a conclusion, Sam
Shemie (McGill University) presented a review of the
determination of brain death in Canada. The concept of brain
death is medically and legally accepted as death in Canada
and a majority of countries worldwide [19]. Despite this
national and international acceptance of brain death,
however, there is no global consensus in diagnostic criteria
[20]. In the United States the concept is one of whole brain61
death, in the United Kingdom it is one of brainstem death,
and finally in Canada there is no clear distinction between
whole brain death versus brainstem death.
A forum sponsored by the Canadian Council for Donation and
Transplantation (Severe Brain Injury to Neurological
Determination of Brain Death) was held in Canada in April
2003 to reach a national consensus on optimal management
of patients with severe brain injury, and in particular for those
who evolve to brain death. These recommendations are in the
process of national distribution. Shemie drew our attention to
the distinction between brain death (a concept that lacks
clarity) and the neurological determination of brain death
(NDD), which is the process and procedure to determine
death based on neurological criteria. The current evidence
base for existing NDD guidelines is inadequate, and clear
standards for NDD and the qualifications of physicians
performing NDD need to be clarified.
A variety of recommendations came out of this Canadian
forum. Accordingly, their definition of NDD was irreversible
loss of the capacity of consciousness combined with the
irreversible loss of brainstem reflexes, including the capacity
to breathe. The physicians performing this testing must have
an independent license and have skill and knowledge in the
care of brain-injured patients. Recommendations were put
forth for the minimal clinical criteria for NDD, including the
appropriate brain stem reflexes to be tested. Confounding
factors need to be absent in the diagnosis of brain death,
such as shock, hypothermia (<34°C), metabolic disorders
causing reversible coma, nerve or muscle dysfunction
accounting for unresponsiveness, and medications or toxins
accounting for the clinical state. With regards to the apnea
test, the recommendation was to achieve PaCO2 ≥60mmHg
and ≥20mmHg above baseline, and pH ≤7.28. A physician
also needs to observe the patient throughout the entire test.
The panel concluded that there is no medical basis for the
existing laws stating that two determinations of death are
required for organ donation. This led to the recommendation
that although two determinations of brain death are required
by law, there should be no fixed examination interval. Finally,
NDD is primarily a clinical diagnosis, which only requires
ancillary testing if there is an inability to complete any of the
minimum clinical examination criteria or there are
confounding factors that cannot be resolved. In this situation
the ancillary test must demonstrate the absence of
intracranial blood flow to diagnose brain death.
Electroencephalogram is no longer recommended.
The report also focused on a variety of other issues including
timing of declaration, reporting and legal issues surrounding
brain death. It should also be noted that the forum had
specific recommendations for children younger than 1 year of
age and newborns that differ from the aforementioned
recommendations.
Nosocomial infections
Nosocomial infections affect about 30% of patients in ICUs
and are on the increase [21]. The Sepsis Occurrence in the
Acutely Ill Patient study undertaken by the European Sepsis
Network taught us that Gram-negative and Gram-positive
infections seem to be equally prevalent. This study also
showed increased mortality and increased ICU length of stay
in patients who acquired a nosocomial infection. The lungs
seem to be the most common location of infection. During his
presentation, Vincent reviewed possible modalities to reduce
the incidence of ventilator-associated pneumonia (VAP),
including noninvasive ventilation, selective digestive
decontamination and continuous subglottic aspiration [21].
He concluded by promoting an integrated care team for
infected ICU patients. This team should include a
microbiologist, an infectious disease consultant, infection
control and a pharmacist.
Gram-positive organisms are the most common source of
bacteremia in the ICU and their prevalence is increasing, as
is the problem of antibiotic resistance. In particular,
methicillin-resistant Staphylococcus aureus is a significant
problem in industrialized nations [22]. Mervyn Singer
(London, UK) acknowledged that the dilemma is becoming
particularly bad in the United Kingdom, with specific regions
affected by methicillin-resistant Staphylococcus aureus [23].
The question of how to adequately treat Gram-positive
bacteremia is not so clear. The duration of therapy has
traditionally been extended in comparison with other bacterial
infections. However, whether this is appropriate is uncertain.
It seems that if a microbiologist becomes involved in the care
of these patients, then the treatment courses are usually
shorter in duration. Current treatment options include
glycopeptides (vancomycin), synercid and linezolid.
The long-standing dogma of isolating these patients must
also be looked at more critically. Singer emphasized that
isolated patients may actually receive suboptimal care with
less frequent visits be the medical team [24]. In addition, the
isolation does not seem to reduce cross-infection rates in
high prevalence units. In summary, Singer impressed upon
the audience that methicillin-resistant Staphylococcus aureus
is probably here to stay and that the best combination of
antibiotics and infection control practices remains to be
determined.
Improving diagnostic precision and the appropriate utilization
of antibiotics may be one strategy to reduce the emergence
of multiresistant pathogens. Using VAP as a model for
discussion, Heyland reviewed the ‘Impact of diagnostic
strategies on patient outcome’. VAP has an attributable
mortality of 5.8% and increases the length of stay by
4.3 days [25]. The importance of correct antibiotic selection
from the start of treatment was stressed, since inappropriate
antibiotic coverage from the outset has been shown to
increase morbidity and mortality [26–28]. Therefore, if VAP is
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strongly suspected, the empiric use of broader spectrum
antibiotics is probably the best approach. However, the use
of broad-spectrum antibiotics can lead to increased
resistance, cost and toxicity. To help combat these
drawbacks of broad-spectrum antibiotics, Heyland proposed
a ‘de-escalation’ of antibiotic coverage once culture results
are available. There is presently no gold standard for the
diagnosis of VAP.
The use of bronchoscopy to help diagnose VAP has been
shown to alter the amount and types of antibiotics used, but
the effect on mortality is questionable [29–32]. Heyland also
eluded to the use of serum-based markers, such as
procalcotonin, IL-6 and IL-8, to help diagnose VAP in the
future [33]. A novel method of ruling out the diagnosis is
through the interpretation of the waveform that is generated
during the performance of the partial thromboplastin time
assay. The presence of an abnormal waveform is associated
with increased mortality and can be a sensitive and specific
indicator of disseminated intravascular coagulation. The
waveform changes may also precede the onset of clinical
disease by 48 hours [34]. There seems to be a high negative
predicative value if a specific type of waveform is absent,
possibly helping to rule out infection.
Although not classically felt to be a nosocomial infection, the
threat of spread through donated blood makes West Nile a
potential nosocomial pathogen. The potential impact on
critically ill patients was highlighted in a report that reviewed
the spread of West Nile to several solid organ transplant
patients. They acquired the disease from an infected donor
who initially was exposed from blood he received during his
initial resuscitation for multiple trauma [35]. In his
presentation, James Brunton (University of Toronto) reviewed
the epidemiology and effects of the West Nile virus. The
cases of West Nile are both geographically and temporally
localized. The disease is most prevalent in the northeastern
United States and the highest incidence occurs in August
and September. However, there has been a gradual
westward progression of the disease in the past few years.
The clinical course of West Nile follows a very generalized
pattern, which unfortunately can make it hard to diagnose.
The prodrome is generally 2–7 days followed by delirium,
which is often attributed to another etiology. The patient may
then deteriorate and have a decreased level of
consciousness, a lower motor neuron pattern of weakness
and respiratory failure. The recovery phase can be varied in
duration and at times protracted. Diagnosis can be aided by
West Nile viral cultures and serology. In fact, blood is now
tested prior to donation, which should hopefully reduce the
risk of transmission. The treatment of West Nile is really just
in its infancy. Intravenous immune globulin has experienced
conflicting results in case reports. Interferon alpha 2b is an
investigational treatment that may offer hope. Finally, human
trials may be on the horizon for the development of a vaccine.
Novel strategies for the treatment of sepsis
Several targets for modulation of the inflammatory response
have been identified and are a source of ongoing
investigations. One such treatment target is the high mobility
group B1 (HGMB1), a nonhistone chromosomal protein.
There is evidence that HGMB1 may be involved as a late
mediator of inflammation with cytokine-like activities [36]. It is
capable of inducing lung injury, liver injury and gut injury in
mice [37,38]. Mitchell Fink (University of Pittsburgh)
presented his research on novel strategies for inhibiting the
effects of HGMB1. The administration of ethyl pyruvate has
been shown to successfully modulate the inflammatory
response in animal models of sepsis. Work is underway to
evaluate its effects in humans. Other potential modulators of
HGMB1 include an anti-HGMB1 monoclonal antibody and a
recombinant segment (box A) of HGMB1 [39]. Interestingly,
it seems that strategies targeting HGMB1 may potentially
offer benefit even in late sepsis.
Gregory Downey (University of Toronto) succinctly reviewed
the importance of the modulation of signaling pathways in
sepsis and in lung injury. The mechanisms of lung injury are
complex and can be divided into early (proximal) and late
events. One of the first events is bacterial endotoxin
lipopolysaccharide binding to toll-like receptors. If this pathway
can be interrupted early then the cascade that follows may be
stopped or reduced. One possible way to achieve this is by
the use of agents that bind lipopolysaccharide, such as
antibodies. Techniques to interrupt in the later stages of the
sepsis cascade include antioxidants, such as alpha-tocopherol
(vitamin E). Interruption of these late stages has been shown in
murine models to confer protection even if given 1 hour after
the initiating stimulus.
Singer concluded this section by providing an interesting
teleological perspective on multi-organ failure (MOF). He
proposed that MOF represents cellular shutdown and is a late-
stage adaptive response to a prolonged insult. He challenged
the audience that meddling with the immune response to
prevent MOF may be counter-productive. In defense of this
proposal, Singer argued that tissue oxygen levels increase and
oxygen consumption decreases during sepsis [40–42]. This is
associated with mitochondrial inhibition, yet ATP levels are
often preserved [43]. Indeed, during MOF there is little
histological evidence of cell death, and if the patient survives
so do the organs [44,45]. In a sense, the cells of major organ
systems go into a state of hibernation and re-emerge when the
illness is resolving. The analogy of hibernation not only applies
to the animal kingdom, but can also be appreciated in the
phenomenon of ‘hibernating’ myocardium. Cellular shutdown
leading to organ failure may thus just be an adaptive response
or a ‘last-ditch’ effort at organ preservation.
Mechanical ventilation
The session surrounding mechanical ventilation began with
Tom Stewart’s (University of Toronto) discussion of lung
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recruitment. Lung recruitment may have a role in cases of
difficult oxygenation or ventilation and as an early protective
strategy in patients with acute lung injury. Evidence does
suggest that recruitment maneuvers lead to increased
oxygenation, at least in the short term [46]. The success of
lung recruitment maneuvers to increase the PaO2/FiO2 ratio
depends on the stage of acute respiratory distress syndrome
(ARDS), with increased success early in the course. Other
factors include the severity of illness, the type of ARDS,
patient positioning and positive end-expiratory pressure
settings postmaneuver [47–50]. Recruitment maneuvers
have been shown to have low complication rates, with
hemodynamic consequences being the most frequent [48].
There are a variety of ways to perform recruitment
maneuvers, but most of the maneuvers require the patient to
be heavily sedated. Stewart also presented some promising
interim analysis of the Lung Open Ventilation Study
demonstrating the safety of recruitment maneuvers.
On the flip side of the previous topic, Brian Kavanagh
(University of Toronto) presented the implications of lung
derecruitment. He stressed that there are a variety of
etiologies of lung derecruitment and that atelectasis is not
straightforward [51]. The impact of atelectasis on the
pulmonary vasculature may be greater than appreciated. In
addition, atelectasis may lead to lung injury directly, through
changes in microvascular permeability [52]. The
effectiveness of modalities to reverse this injury depends on
timing, the nature of the lung injury and the approach used.
The utility of early prevention of derecruitment requires
further study.
‘The chest wall vs. the abdomen’ was the subject presented
by Antonio Pesenti (Ospedale S. Gerardo, Monza, Italy). He
eloquently described the physiological interaction between
the abdomen and the chest wall during the respiratory
cycle. In the supine patient the pressure of the abdominal
contents is directed on the diaphragm in a cephelad
direction. This subsequently causes atelectasis in the
dependent lung zones near the diaphragm. Increases in
both chest wall compliance and abdominal pressure will
exaggerate this effect. In fact, by decreasing chest wall
compliance through the experimental use of weights
directly applied to the chest wall, one can demonstrate a
reduction in V/Q mismatch and an improvement in
oxygenation. Pesenti left the audience with four simple
words to remind us of the importance of the abdomen in
respiratory mechanics: ‘breathe with your belly’.
Arthur Slutsky (University of Toronto) followed with the topic
‘Mechanical ventilation and multiple organ dysfunction’. The
lung seems to be in a unique situation to contribute to
multiple organ dysfunction. It receives all of the systemic
circulation and contains 25–50% of the marginated
neutrophil pool. A variety of studies have suggested the
connection between lung injury and multiple organ
dysfunction. In particular, lung overinflation without positive
end-expiratory pressure has been demonstrated to promote
bacteremia, and there is pulmonary to systemic translocation
of endotoxin [53,54]. In addition, Slutsky discussed ongoing
animal research that is looking into the relationship of injurious
ventilatory strategies and apoptosis of organs distal to the
lung (e.g. kidney, gut). A reduction in cell death was noted in
the lung protective strategies in this animal model. Overall,
both biochemical and biomechanical injury to the lungs
causes the release of a variety of inflammatory mediators,
such as cytokines, complement and neutrophils [55]. These
mediators in turn may lead to MOF and contribute to the
morbidity and mortality beyond the initial lung injury.
As many of the aforementioned studies have noted,
mechanical ventilation can lead to injury to both the lung and
to other organs. Evidence is mounting that lung protective
strategies may reduce the harm to patients secondary to
injurious methods of ventilation. However, the knowledge of
lung protective strategies has not translated into their
widespread use in practice. Gordon Rubenfeld (Washington
University) cited many reasons for this discord. Failure to
recognize mild forms of acute lung injury/ARDS and lack of
knowledge surrounding lung protection are continuing
problems. In addition, physician reluctance was seen as a
barrier to implementation. The solution to this failure to apply
the literature to everyday practice requires several
approaches. Better training and improved documentation of
patient’s ventilation parameters at the bedside are starting
points. However, Rubenfeld indicated that standard
protocols for ventilation might be the most efficient and
effective solution.
In a case of what is old is new again, the issues surrounding
surfactant in lung-injured patients were revisited by Neil
MacIntyre (Duke University). The rationale for using surfactant
includes better mechanical function, anti-inflammatory
properties and strong evidence in infant respiratory distress
syndrome and in animal models. Improved mechanical function
relates to less regional overdistention when adequate
surfactant is available. Previous attempts to study the use of
surfactant replacement in ARDS have not shown an
improvement in outcome. However, these studies were
complicated by inefficient delivery systems and surfactant
preparations that may have been inadequate [56]. More recent
studies have pointed to improved oxygenation and possibly a
trend towards decreased mortality [57]. Issues that may be
important in the effectiveness of surfactant as a therapy include
the nature of the lung injury (direct versus indirect), the timing,
the protein/phospholipid content and the dosing route.
The emerging technology of neurally controlled ventilators
was presented by Christer Sinderby (University of Toronto).
Asynchrony between the patient and the ventilator is common
in the critically ill. This often leads to ineffective ventilation, to
ventilator-related complications (e.g. pneumothorax) and to
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increases in sedation. Neurally controlled ventilators would
have the timing and possibly the magnitude of ventilatory
assistance controlled via a neural input from the patient.
Diaphragmatic electrical activity can be monitored and can
act as a signal to in effect “inform” the ventilator about a
patient’s respiratory cycle. With neurally adjusted ventilators
the amount of mechanical support varies from moment to
moment according to a mathematical function that converts
diaphragmatic electrical activity to ventilator flow and
pressure. This mode of ventilation has significant relevance
as it stands to improve patient–ventilator synchrony, to
reduce requirements for sedation and to facilitate weaning.
Future research includes the use of neural-controlled
ventilation in neonates and as a noninvasive modality [58].
After patients leave the critical care unit many critical care
staff lose contact with them and have little perspective on
their quality of life in the future. Margaret Herridge (University
of Toronto) presented a review of research looking at long-
term outcomes in patients with ARDS [59]. Patients were
assessed 3, 6 and 12 months after discharge from the critical
care unit. With regards to the pulmonary function tests, the
lung volumes approached normal values by the 12-month
mark, but the diffusion capacity remained substantially lower
than predicted. The distance walked over 6 min (a measure
of patient functioning) was less than predicted at 12 months.
This was attributed to global muscle weakness and wasting,
to foot drop, to immobility of large joints and to dyspnea.
Surprisingly, 49% of patients had returned to work 1 year
after discharge, with the majority in their original position. The
absence of systemic corticosteroids, the lack of acquired
illness during the ICU stay and the rapid resolution of lung
injury were associated with higher functional levels at 1 year.
Herridge’s data call upon us to evaluate strategies to improve
patient outcomes further by altering how we care for patients
in the ICU (steroids, neuromuscular blockade, nutrition) as
well as developing programs to promote rehabilitation both
during and after the patient’s ICU stay. Herridge’s results
challenge us to expand the role of the ICU physician as an
advocate for patient care during their convalescence.
Pesenti wrapped up the session on mechanical ventilation
with his talk ‘How I manage ARDS’. He began by reminding
the audience that mechanical ventilation and ARDS are
highly linked. With this in mind, should we be attempting to
ventilate non-normal critically ill patients to normal lung blood
gases? There is a price to pay for attempting this. With
controlled mechanical ventilation our goals should be low
tidal volumes and low plateau pressures. Permissive
hypercapnia allows greater latitude in providing these less
injurious ventilations to the patient with ARDS [60,61].
Pesenti presented his rationale for the use of volume control
over pressure control ventilation. The use of higher levels of
positive end-expiratory pressure and recruitment maneuvers
(including prone positioning) was encouraged. In his
discussion of prone positioning, Pesenti reviewed the
available data and suggested that a good indicator of survival
in the prone patient is the responsiveness of the PaCO2. The
benefits of early weaning and conversion to pressure support
ventilation were also stressed. Studies have shown that
selected groups of ventilated patients can tolerate pressure
support very well early in their ICU course [62]. These
patients get the benefits of pressure support earlier, which
include less sedation, decreased intrathoracic pressure,
improved tidal volume distribution and less respiratory
muscle atrophy.
Conclusion
This summary is just a sample of the presentations at the
2003 Toronto Critical Care Medicine Symposium. Many
other presentations touched on subjects including medical
errors, sedation, team building, management of cardiac
failure and specific pediatric critical care issues. Particularly
entertaining sessions were several pro/con debates that
occurred at the end of the symposium. The topics debated
were lung protective strategies, nontherapeutic ventilation
and genomics.
Overall the 3-day conference was an enormous success.
Planning is already underway for next year, 21–23 October
2004. Save the dates.
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